Ex­clu­sive: Eli Lil­ly boosts in­flam­ma­to­ry dis­ease pipeline, li­cens­es three can­di­dates from TRexBio

Eli Lil­ly is adding three new pre­clin­i­cal can­di­dates to its im­mune and in­flam­ma­to­ry med­i­cines ar­mory through TRexBio, a Bay Area biotech that spe­cial­izes in T reg­u­la­to­ry cells, or Tregs.

In ex­change for glob­al li­cens­es on the can­di­dates — TRB-051, TRB-031, and TRB-041 — TRexBio will get $55 mil­lion up­front. All in all, TRexBio could get over $1.1 bil­lion when fac­tor­ing in down­stream mile­stones. Ac­cord­ing to TRexBio’s web­site, TRB-051 is the fur­thest along, in the IND-en­abling phase.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER